SarCNU in recurrent or metastatic colorectal cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group

Investigational New Drugs
R P WongNational Cancer Institute of Canada Clinical Trials Group

Abstract

To evaluate the activity and toxicity of SarCNU, an oral chloroethylnitrosourea in patients with recurrent or metastatic colorectal cancer who have progressed after first-line chemotherapy. Eighteen patients with recurrent or metastatic colorectal cancer following first-line chemotherapy were treated with SarCNU 860 mg/m2 orally day 1, 5 and 9 every 6 weeks. The patient's median age was 64 and the ECOG performance status was 0 in six, 1 in eleven and 2 in one patients. All patients were evaluable for toxicity and 16 were evaluable for response. There were no objective responses (0%). One patient had stable disease and 15 had progressive disease at their first follow-up assessment. Median survival was 7.36 months (3.75-7.49 95% C.I.). Neutropenia and thrombocytopenia were the most severe toxicities (grade 3-4 in six and nine patients respectively). Pulmonary toxicity was also seen in five patients who had a drop of DLCO grade from baseline and two patients who had a fall in FVC from baseline. SarCNU is inactive in recurrent or metastatic colorectal patients who have progressed after first-line chemotherapy.

References

Jun 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Nordic Gastrointestinal Tumor Adjuvant Therapy Group
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L PanasciE Sausville
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Axel GrotheyHans-Joachim Schmoll

❮ Previous
Next ❯

Citations

May 4, 2007·Pharmaceutical Statistics·Scott D Patterson, Byron Jones
Aug 31, 2011·Journal of Cancer Research and Clinical Oncology·Jonas Cicenas, Mindaugas Valius
Aug 19, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mrinal M GounderPatrick Y Wen
Jun 18, 2019·The Cochrane Database of Systematic Reviews·Charlene J TreanorMichael Donnelly

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.